The Multidisciplinary Association for Psychedelic Studies (MAPS)  is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS Canada was formed in 2008 to develop programs in Canada. Since our founding in 1986, MAPS has disbursed over $27 million to psychedelic and medical marijuana research and education. We currently estimate that MDMA-assisted psychotherapy will be approved as a prescription treatment in 2021—that's just four years. With our goal increasingly in reach, we are exploring how best to leverage the prescription use of MDMA-assisted psychotherapy and potential income from legal sales of MDMA into a source of support for the continued development of psychedelic science, medicine, and education. By making a contribution, you're helping make psychedelic therapy a legally available treatment.